Supplementary Figures 1-5 from Resistance Mechanisms to Targeted Therapies in &lt;i&gt;ROS1&lt;/i&gt;&lt;sup&gt;+&lt;/sup&gt; and &lt;i&gt;ALK&lt;/i&gt;&lt;sup&gt;+&lt;/sup&gt; Non–small Cell Lung Cancer